BioWorld

July 27, 2007

View Archived Issues

Hydra Lands Potential $195M Deal With Pfizer On Pain Drugs

Hydra Biosciences Inc. licensed rights to its TRPV3 antagonist program to Pfizer Inc. in a deal valued at up to $195 million. (BioWorld Today) Read More

Exelixis Moving Forward On XL647 After GSK Declines

Read More

ATP Sense Channels Link Spinal Cord Injury, Stroke, Diabetes

Read More

Aspreva Restructures, Plans To Look Beyond CellCept

Read More

Revlimid Sales Drive Celgene's Second-Quarter Revenue Growth

Read More

Other News To Note

Read More

Clinic Roundup

Read More